Mayne Pharma Group Statistics

Total Valuation

Mayne Pharma Group has a market cap or net worth of AUD 363.54 million. The enterprise value is 253.08 million.

Market Cap	363.54M
Enterprise Value	253.08M

Important Dates

The next estimated earnings date is Monday, November 25, 2024.

Earnings Date	Nov 25, 2024
Ex-Dividend Date	n/a

Share Statistics

Mayne Pharma Group has 81.15 million shares outstanding. The number of shares has decreased by -3.11% in one year.

Current Share Class	n/a
Shares Outstanding	81.15M
Shares Change (YoY)	-3.11%
Shares Change (QoQ)	-1.83%
Owned by Insiders (%)	8.69%
Owned by Institutions (%)	31.62%
Float	65.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.92
PB Ratio	0.80
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.20, with an EV/FCF ratio of -10.89.

EV / Earnings	-1.45
EV / Sales	0.65
EV / EBITDA	11.20
EV / EBIT	n/a
EV / FCF	-10.89

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.09.

Current Ratio	1.47
Quick Ratio	1.14
Debt / Equity	0.09
Debt / EBITDA	1.72
Debt / FCF	-1.67
Interest Coverage	-9.47

Financial Efficiency

Return on equity (ROE) is -30.98% and return on invested capital (ROIC) is -4.74%.

Return on Equity (ROE)	-30.98%
Return on Assets (ROA)	-2.33%
Return on Capital (ROIC)	-4.74%
Revenue Per Employee	401,654
Profits Per Employee	-180,179
Employee Count	967
Asset Turnover	0.32
Inventory Turnover	2.16

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.47% in the last 52 weeks. The beta is 1.24, so Mayne Pharma Group's price volatility has been higher than the market average.

Beta (5Y)	1.24
52-Week Price Change	-6.47%
50-Day Moving Average	4.63
200-Day Moving Average	5.27
Relative Strength Index (RSI)	45.30
Average Volume (20 Days)	237,850

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mayne Pharma Group had revenue of AUD 388.40 million and -174.23 million in losses. Loss per share was -2.19.

Revenue	388.40M
Gross Profit	218.78M
Operating Income	-44.54M
Pretax Income	-190.09M
Net Income	-174.23M
EBITDA	18.80M
EBIT	-44.54M
Loss Per Share	-2.19

Full Income Statement

Balance Sheet

The company has 149.28 million in cash and 38.82 million in debt, giving a net cash position of 110.46 million or 1.36 per share.

Cash & Cash Equivalents	149.28M
Total Debt	38.82M
Net Cash	110.46M
Net Cash Per Share	1.36
Equity (Book Value)	454.19M
Book Value Per Share	5.59
Working Capital	146.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.30 million and capital expenditures -7.95 million, giving a free cash flow of -23.25 million.

Operating Cash Flow	-15.30M
Capital Expenditures	-7.95M
Free Cash Flow	-23.25M
FCF Per Share	-0.29

Full Cash Flow Statement

Margins

Gross margin is 56.33%, with operating and profit margins of -11.47% and -44.86%.

Gross Margin	56.33%
Operating Margin	-11.47%
Pretax Margin	-48.94%
Profit Margin	-44.86%
EBITDA Margin	4.84%
EBIT Margin	-11.47%
FCF Margin	-5.99%

Dividends & Yields

Mayne Pharma Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.11%
Shareholder Yield	3.11%
Earnings Yield	-48.90%
FCF Yield	-6.40%

Dividend Details

Stock Splits

The last stock split was on January 18, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 18, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

Mayne Pharma Group has an Altman Z-Score of -0.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.42
Piotroski F-Score	n/a